Ado-trastuzumab emtansine led to improved overall survival and invasive disease–free survival over trastuzumab in patients ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

T-DM1 was tolerable in HER2-positive biliary tract adenocarcinoma but did not significantly improve progression-free survival ...

The firm will share new overall survival data from the INAVO120 trial with regulators to support the breast cancer drug's approval.

T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab in HER2-positive early breast cancer. HealthDay News — For patients with human epidermal growth factor receptor ...

The patients were randomly assigned to receive adjuvant treatment with T-DM1 at 3.6 mg/kg (n=743) or trastuzumab at 6 mg/kg (n=743) every 3 weeks for 14 cycles. Baseline characteristics were ...

Trastuzumab rezetecan is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to GlobalData, Phase II drugs ...

THURSDAY, Jan. 16, 2025 (HealthDay News) — For patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, adjuvant trastuzumab emtansine (T-DM1) improves overall ...

PITTSBURGH — In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by ...

Adjuvant ado-trastuzumab emtansine improved survival compared with trastuzumab for early HER2-positive breast cancer. Long-term follow-up showed a continued DFS benefit with ado-trastuzumab ...